227 related articles for article (PubMed ID: 18343800)
1. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.
ter Heine R; Scherpbier HJ; Crommentuyn KM; Bekker V; Beijnen JH; Kuijpers TW; Huitema AD
Antivir Ther; 2008; 13(6):779-87. PubMed ID: 18839779
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children.
Viljoen M; Gous H; Kruger HS; Riddick A; Meyers TM; Rheeders M
AIDS Res Hum Retroviruses; 2010 Jun; 26(6):613-9. PubMed ID: 20507205
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
McKinney RE; Rodman J; Hu C; Britto P; Hughes M; Smith ME; Serchuck LK; Kraimer J; Ortiz AA; Flynn P; Yogev R; Spector S; Draper L; Tran P; Scites M; Dickover R; Weinberg A; Cunningham C; Abrams E; Blum MR; Chittick GE; Reynolds L; Rathore M;
Pediatrics; 2007 Aug; 120(2):e416-23. PubMed ID: 17646352
[TBL] [Abstract][Full Text] [Related]
7. Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.
Mutwa PR; Fillekes Q; Malgaz M; Tuyishimire D; Kraats Rv; Boer KR; Burger DM; van Schaik RH; Muganga N; Geelen SP
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):400-4. PubMed ID: 22481606
[TBL] [Abstract][Full Text] [Related]
8. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.
von Hentig N; Koenigs C; Elanjikal S; Linde R; Dunsch D; Kreuz W; Funk MB
Eur J Med Res; 2006 Sep; 11(9):377-80. PubMed ID: 17101460
[TBL] [Abstract][Full Text] [Related]
9. [Evidence-based therapeutic drug monitoring for efavirenz].
Solas C; Gagnieu MC;
Therapie; 2011; 66(3):197-205. PubMed ID: 21819803
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
Soeria-Atmadja S; Österberg E; Gustafsson LL; Dahl ML; Eriksen J; Rubin J; Navér L
PLoS One; 2017; 12(9):e0181316. PubMed ID: 28886044
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
[TBL] [Abstract][Full Text] [Related]
12. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
14. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Friedland G; Khoo S; Jack C; Lalloo U
J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
[TBL] [Abstract][Full Text] [Related]
15. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
17. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.
Meynard JL; Lacombe K; Poirier JM; Legrand J; Morand-Joubert L; Girard PM
J Antimicrob Chemother; 2009 Mar; 63(3):579-84. PubMed ID: 19168543
[TBL] [Abstract][Full Text] [Related]
18. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
19. Minimum effective plasma concentration of efavirenz in treatment-naïve Chinese HIV-infected patients.
Sun J; Chen J; Yao Y; Zhang R; Zheng Y; Liu L; Zhang L; Shen Y; Lu H
Int J STD AIDS; 2010 Dec; 21(12):810-3. PubMed ID: 21297088
[TBL] [Abstract][Full Text] [Related]
20. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
